Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Comments for:

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor
Gerd Wallukat, … , Hermann Haller, Friedrich C. Luft
Gerd Wallukat, … , Hermann Haller, Friedrich C. Luft
Published April 1, 1999
Citation Information: J Clin Invest. 1999;103(7):945-952. https://doi.org/10.1172/JCI4106.
View: Text | PDF
Article

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor

  • Text
  • PDF
Abstract

Immune mechanisms and the renin–angiotensin system are implicated in preeclampsia. We investigated 25 preeclamptic patients and compared them with 12 normotensive pregnant women and 10 pregnant patients with essential hypertension. Antibodies were detected by the chronotropic responses to AT1 receptor–mediated stimulation of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists. Immunoglobulin from all preeclamptic patients stimulated the AT1 receptor, whereas immunoglobulin from controls had no effect. The increased autoimmune activity decreased after delivery. Affinity-column purification and anti–human IgG and IgM antibody exposure implicated an IgG antibody directed at the AT1 receptor. Peptides corresponding to sites on the AT1 receptor's second extracellular loop abolished the stimulatory effect. Western blotting with purified patient IgG and a commercially obtained AT1 receptor antibody produced bands of identical molecular weight. Furthermore, confocal microscopy of vascular smooth muscle cells showed colocalization of purified patient IgG and AT1 receptor antibody. The protein kinase C (PKC) inhibitor calphostin C prevented the stimulatory effect. Our results suggest that preeclamptic patients develop stimulatory autoantibodies against the second extracellular AT1 receptor loop. The effect appears to be PKC-mediated. These novel autoantibodies may participate in the angiotensin II–induced vascular lesions in these patients.

Authors

Gerd Wallukat, Volker Homuth, Thorsten Fischer, Carsten Lindschau, Björn Horstkamp, Axel Jüpner, Evi Baur, Eberhard Nissen, Klaus Vetter, Dajana Neichel, Joachim W. Dudenhausen, Hermann Haller, Friedrich C. Luft

×

AT1 autoantibodies due to HLA-DR molecular mimicry?

Submitter: Charles J. Hoff, Ph.D. | choff@usamail.usouthal.edu

College of Medicine, University of South Alabama, Mobile, AL 36608

Published April 22, 1999

Wallukat et al. (1) have reported that preeclamptic women have IgG autoantibodies to the angiotensin AT1 vascular receptor whereas nonpregnant and normotensive pregnant women do not. Their findings implicate the second extracellular loop of the AT1 molecule as the reactive site. Labarrere and Faulk (2) have found that fetal HLA-DR antigens are expressed in the endovascular cytotrophoblasts in the uteroplacental arteries of preeclamptic women, but not in normotensive women. They speculate that when paternally-derived fetal HLA-DR antigens are allogeneic, this expression may cause a maternal immune response contributing to the development of preeclampsia. Because autoimmune responses are rare events in young adults, a possible explanation for the occurrence of anti-AT1 autoantibody in preeclampsia is the production of cross-reactive anti-fetal HLA-DR antibody resulting from HLA-DR allogenicity combined with homology between the constant regions of fetal HLA-DR alloantigens and the AT1 receptor.
Using the ENTREZ browser (3), I obtained the peptide sequences of human AT1 (gi code: 4501997) and the HLADRalpha (gi: 122206) and HLA- DRbeta chains (gi: 2529486). I next compared the peptide sequences of these two proteins using the local sequence alignment program, LALIGN (4), to determine whether any homology existed. The HLA-DRalpha chain showed the most homology with AT1. Only those pairs of segments containing three or more amino acids in sequence for the HLA-DRalpha chain and AT1 are reported here.
Comparing AT1 with HLA-DRalpha, I found four pairs of segments showing homology. There were two sets of segment-pairs of 18 amino acids with 33.3% homology, one segment-pair of 37 amino acids with 27% homology, and one segment-pair of 10 amino acids with 50% homology. The latter AT1 homology was within the reactive site of the second extracellular loop which the authors noted in their paper (1).
These findings suggest that it is possible anti-fetal HLA-DR antibodies may be produced in preeclampsia which are cross-reactive and target the AT1 receptor. If this is the case, they may contribute to the vasculopathy underlying preeclampsia.
1. Wallukat, G. et al. 1999. Patients with preeclampsia develop agonistic autoantibodies against angiotensin AT1 receptor. J. Clin. Invest. 103:945-952.
2. Labarrere, C.A. and Faulk, W.P. 1995. Intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigens are expressed on endovascular cytotrophoblast in abnormal pregnancies. Am. J. Reprod. Immunol. 33:47- 53.
3. National Center for Biotechnology Information. ENTREZ Browser. http://www.ncbi.nlm.nih.gov/Entrez/. April 1999.
4. Huang, X. and Miller W. 1991 LALIGN. Adv. Appl. Math. 12:373-381.

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts